Inzolfi (Fingolimod)

Fingolimod is a selective modulator of sphingosine‑1‑phosphate receptors on lymphocytes. By binding to S1P1 receptors, it causes receptor internalisation, preventing lymphocytes from leaving lymph nodes. This reduces the number of circulating lymphocytes that can enter the central nervous system, thereby diminishing inflammatory attacks that lead to demyelination in multiple sclerosis.

The dosing regimen for Inzolfi is determined by the prescribing physician based on the patient’s clinical condition, laboratory values, and applicable regulatory guidelines. The prescriber selects the appropriate strength and administration schedule, and patients should follow the healthcare professional’s instructions without deviation.

Fingolimod is contraindicated during pregnancy because it may cause fetal harm, and it is not recommended for breastfeeding mothers as it can be excreted in breast milk. Women of child‑bearing potential should use effective contraception and discuss family planning with their healthcare provider before starting therapy.

To request Inzolfi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to fingolimod is dimethyl fumarate or other disease‑modifying therapies such as interferon‑β. Compared with interferon‑β, fingolimod offers oral administration and a mechanism that directly reduces lymphocyte egress, but it carries distinct safety considerations, including cardiac monitoring and infection risk, which must be weighed by the treating physician.

Inzolfi should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or near heat sources. No refrigeration is required for this oral formulation.

Inzolfi is taken orally, usually as a tablet swallowed whole with water. The medication is intended for once‑daily use, and patients should take it at the same time each day to maintain consistent blood levels. It may be taken with or without food as directed by the prescribing clinician.

The most serious risks associated with fingolimod include severe infections, cardiac events such as bradyarrhythmia or heart block, macular edema affecting vision, and significant liver enzyme elevations. Patients should promptly report persistent fever, chest pain, visual changes, or jaundice to their healthcare provider.

Inzolfi is contraindicated in patients with known hypersensitivity to fingolimod, those with active infections, severe cardiac conditions, or a history of stroke. It is also prohibited during pregnancy and in women who are breastfeeding. Individuals with significant liver impairment or uncontrolled hypertension should be evaluated carefully before use.